Source link : https://newshealth.biz/health-news/bispecific-antibody-boosts-survival-in-relapsed-refractory-multiple-myeloma/
CHICAGO — Teclistamab (Tecvayli) monotherapy significantly improved survival compared with standard therapies in patients with multiple myeloma who had received up to three previous lines of therapy, the phase III MajesTEC-9 trial showed. The estimated 18-month progression-free survival (PFS) rate was 69.8% with teclistamab compared with 26.9% with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) […]
The post Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-29 20:37:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8